Ποια είναι η τιμή για Apexigen, Inc. (APGN)

Η τιμή για Apexigen, Inc. (APGN) είναι $0.385

Ποια είναι η κεφαλαιοποίηση αγοράς για Apexigen, Inc. (APGN)

Η κεφαλαιοποίηση αγοράς για Apexigen, Inc. (APGN) είναι $2.86M

Apexigen, Inc. (APGN) Τιμή και Κεφαλαιοποίηση Αγοράς

Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.

Η τιμή για APGN	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$733,292 $2.86M	NVDA	$5.452T	+190,465,470.05%
$603,921 $2.86M	AAPL	$4.490T	+156,862,518.99%
$559,856 $2.86M	GOOG	$4.162T	+145,417,078.91%
$494,479 $2.86M	MSFT	$3.676T	+128,436,005.32%
$381,053 $2.86M	AMZN	$2.833T	+98,974,619.32%

Η τιμή για APGN

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$733,292 $2.86M